A CRISPR/CAS9‐based strategy targets the personalized chimeric neosequence in fusion‐driven cancer genome for precision medicine
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-03-01
|
| Series: | Clinical and Translational Medicine |
| Online Access: | https://doi.org/10.1002/ctm2.355 |